RT Journal Article
SR Electronic
T1 Long-term antibody response to SARS-CoV-2 in children
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.11.22270611
DO 10.1101/2022.02.11.22270611
A1 Dunay, Gabor A.
A1 Barroso, Madalena
A1 Woidy, Mathias
A1 Danecka, Marta K.
A1 Engels, Geraldine
A1 Hermann, Katharina
A1 Neumann, Friederike S.
A1 Paul, Kevin
A1 Beime, Jan
A1 Escherich, Gabriele
A1 Fehse, Kristin
A1 Grinstein, Lev
A1 Haniel, Franziska
A1 Haupt, Luka J.
A1 Hecher, Laura
A1 Kehl, Torben
A1 Kemen, Christoph
A1 Kemper, Markus J.
A1 Kobbe, Robin
A1 Kohl, Aloisa
A1 Klokow, Thomas
A1 Nörz, Dominik
A1 Olfe, Jakob
A1 Schlenker, Friderike
A1 Schmiesing, Jessica
A1 Schrum, Johanna
A1 Sibbertsen, Freya
A1 Stock, Philippe
A1 Tiede, Stephan
A1 Vettorazzi, Eik
A1 Zazara, Dimitra E.
A1 Zapf, Antonia
A1 Lütgehetmann, Marc
A1 Oh, Jun
A1 Mir, Thomas S.
A1 Muntau, Ania C.
A1 ,
A1 Gersting, Søren W.
YR 2022
UL http://medrxiv.org/content/early/2022/02/11/2022.02.11.22270611.abstract
AB Almost two years into the pandemic and with vaccination of children significantly lagging behind adults, long-term pediatric humoral immune responses to SARS-CoV-2 are understudied. The C19.CHILD Hamburg (COVID-19 Child Health Investigation of Latent Disease) Study is a prospective cohort study designed to identify and follow up children and their household contacts infected in the early 2020 first wave of SARS-CoV-2. We screened 6113 children <18 years by nasopharyngeal swab-PCR in a low-incidence setting after general lockdown, from May 11 to June 30, 2020. 4657 participants underwent antibody testing. Positive tests were followed up by repeated PCR and serological testing of all household contacts over 6 months. In total, the study identified 67 seropositive children (1.44 %), the median time after infection at first presentation was 83 days post-symptom onset (PSO). Follow up of household contacts showed incomplete seroconversion in most families, with higher seroconversion rates in families with adult index cases compared to pediatric index cases (OR: 1.79, P=0.047). Most importantly, children showed sustained seroconversion up to nine months PSO, and serum antibody concentrations persistently surpassed adult levels (ratio serum IgG Spike children vs. adults 90 days PSO: 1.75, P<0.001, 180 days: 1.38, P=0.01, 270 days: 1.54, P=0.001).In a low-incidence setting, SARS-CoV-2 infection and humoral immune response present distinct patterns in children including higher antibody levels, and lower seroconversion rates in families with pediatric index cases. Children show long-term SARS-CoV-2 antibody responses. These findings are relevant to novel variants with increased disease burden in children, as well as for the planning of age-appropriate vaccination strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe C19.CHILD Hamburg Study received funding from the Senate Chancellery of the Free and Hanseatic City of Hamburg. The following foundations and organizations have provided financial support: Carlsen Verlag, Dr. Melitta Berkemann Stiftung, Foerdergemeinschaft Kinderkrebs‐Zentrum Hamburg e.V., Freunde der Kinderklinik des UK Eppendorf e.V., HSV Fussball AG, Joachim‐Herz‐Stiftung, Michael Otto Stiftung, Michael Stich Stiftung, Nutricia, Stiftung KinderHerz, EAGLES Charity Golf Club e.V., DAMP Stiftung, Kroschke Stiftung, ZEIT‐Stiftung.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethik-Kommission der Aerztekammer Hamburg Weidestr. 122 b, 22083 HamburgI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors